are glp-1 receptor agonists banned by wada 2025 just added tirzepatide (mounjaro) to the 2026 Monitoring Program GLP-1 Receptor Agonist Market Growth

Boehringer Ingelheim, in collaboration with Zealand Pharma, will likely be the next big challenger after advancing its promising candidate survodutide, a GCGR/GLP-1R dual agonist, to Phase 3 clinical trials last year

Bring the laboratory requisition and required identification

While the FDA approved doses of 0.5 mg and 1.0 mg for diabetes management, the agency has also issued warnings about potential risks including pancreatitis, thyroid cancer concerns based on animal studies, and other serious adverse events

Dakin CL, Gunn I, Small CJ, et al

If this is the case, you still have options: Check if you qualify for partial reimbursement for dietitian visits outside the network, use your HSA or FSA account, see if your employer wellness program includes nutrition counseling, or get in touch with our team to learn more about alternative payment plans for self-paying clients

It is not an over-the-counter substitute for diabetes medication